Latest Regulatory Milestones News

EBR Systems has secured a significant regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) initiates a National Coverage Determination (NCD) for its WiSE wireless cardiac pacing system, aiming for approval by early 2027.

Macarthur Minerals has approved a joint venture where Gold Valley assigns half its interest in the Lake Giles Ularring Hematite Project to Destec, bringing fresh operational expertise to the venture while Macarthur retains full ownership of its tenements.

Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.

PMET Resources has received a non-binding Letter of Interest from Société Générale to act as Mandated Lead Arranger for debt financing of the Phase 1 development of its Shaakichiuwaanaan lithium project in Quebec, advancing its syndicate-building strategy ahead of an updated feasibility study.

Sky Metals has secured a crucial regulatory milestone for its Tallebung tin-silver-tungsten project in NSW, moving into the Environmental Impact Statement phase following the issuance of SEARs by the NSW Department of Planning. The company prepares for imminent resource and feasibility updates that could shape the project’s development trajectory.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Pioneer Minerals has reopened the historic Springfield Mine Road, enabling vehicle access to its North Pine Project in Idaho and slashing exploration costs. This milestone sets the stage for accelerated fieldwork targeting tungsten, gold, and gallium.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

Vita Resources NL is accelerating exploration across its diverse portfolio, expanding drilling at its Ninnis Gold Project in WA and confirming polymetallic upgrades at its ICE Project in Canada.

EV Resources has cleared a critical regulatory hurdle by obtaining the Change of Use of Soil permit for its Tecomatlán Plant, enabling the final environmental report filing and grid connection application that pave the way for near-term antimony production.